Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Hejazi  EZ, Werth  VP.  Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment.  Am J Clin Dermatol. 2016;17(2):135-146.PubMedGoogle ScholarCrossref
2.
Ruzicka  T, Sommerburg  C, Goerz  G, Kind  P, Mensing  H.  Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine.  Br J Dermatol. 1992;127(5):513-518.PubMedGoogle ScholarCrossref
3.
Moghadam-Kia  S, Chilek  K, Gaines  E,  et al.  Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients.  Arch Dermatol. 2009;145(3):255-260.PubMedGoogle ScholarCrossref
4.
Chasset  F, Francès  C, Barete  S, Amoura  Z, Arnaud  L.  Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.  J Am Acad Dermatol. 2015;72(4):634-639.PubMedGoogle ScholarCrossref
5.
Chasset  F, Arnaud  L, Costedoat-Chalumeau  N, Zahr  N, Bessis  D, Francès  C.  The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.  J Am Acad Dermatol. 2016;74(4):693-9.e3.PubMedGoogle ScholarCrossref
6.
Husein-ElAhmed  H, Callejas-Rubio  JL, Rios-Fernandez  R, Ortego-Centeno  N.  Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody.  Indian J Dermatol Venereol Leprol. 2014;80(5):477-478.PubMedGoogle ScholarCrossref
Research Letter
September 2017

Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus

Author Affiliations
  • 1Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, New York
  • 2Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA Dermatol. 2017;153(9):937-939. doi:10.1001/jamadermatol.2017.1160

Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease associated with substantial morbidity.1 Although antimalarial therapy is considered to be first-line systemic treatment, as many as 50% of patients have recalcitrant disease.2 Alternative therapies have been investigated for antimalarial-refractory CLE, but the existing literature is limited to small studies without comparative treatment data.1 We therefore sought to evaluate the characteristics and treatments of antimalarial-refractory CLE.

We performed a query-based search of medical records from New York University Langone Medical Center, New York; Bellevue Hospital Center, New York, New York; Brigham and Women’s Hospital, Boston, Massachusetts; and Massachusetts General Hospital, Boston, to identify patients with antimalarial-refractory CLE from January 1, 2000, through December 31, 2015. Antimalarial-refractory disease was defined as no clinical response (CR) (no improvement in erythema, scaling, and alopecia) or partial CR (<50% improvement) to standard doses of at least 1 antimalarial therapy for at least 3 months. Deidentified clinical and treatment data were extracted, and categorical variables were compared using 2-tailed χ2 tests with Bonferroni post hoc analysis (P ≤ .05). This study was approved by the institutional review boards of all participating institutions.

×